Ebola virus disease (EVD) is a highly lethal contagious disease caused by the negative RNA strand Ebola virus. Reservoired in wild forest animals of Africa, Ebola virus infects humans that come in direct contact of diseased animals and outbreaks of EVD result from person to person spread of infection. A recent EVD outbreak in West Africa has killed several thousand persons. Since Ebola infection will persist in animals, EVD epidemics are expected to continue to occur in future. Infected travellers from Africa can initiate/import outbreaks in countries of other continents. This review describes the properties of the Ebola virus and EVD, the ongoing attempts to develop diagnostics, vaccines and medicines for prevention and cure of EVD and the supportive care that saves some EVD patients. Also discussed are measures that can stop and prevent EVD outbreaks. Need for inclusion of EVD in the education, research, drug and medical equipment manufacturing programmes, of the densly populated countries such as India, is emphasised. 
Introduction
In addition to chikungunya, dengue, swine flu and zika viral diseases, Ebola virus disease (EVD) is a potential public health threat of pandemic proportions for India. It is so, on account of human to human transmission of the Ebola virus via exudates of patients, absence of liscenced vaccine(s) for protection against the disease and of therapeutics for the treatment of disease, continued presence of Ebola virus in its reservoir hosts in the endemic areas of EVD, Ebola virus possessing the properties of category -A biothreat pathogen and high fatality rates in its patients. Since 1976 when EVD was first described, there have been at least 26 outbreaks of EVD in the Central and Western regions of Africa. Out of the two recent EVD outbreaks, smaller one in the Democratic Republic of Congo (WHO 2014a) , the larger one in West Africa in a region comprising of Guinea, Liberia and Sierra Leone (WHO 2014b ) is still in progression and by July 19, 2015, about 11,269 EVD patients had died. Travelers and evacuees from the outbreak region in Africa have carried the disease to Mali, Senegal and Nigeria in Africa and to North America and Europe (en.m.wikipedia.org/wiki/Ebola_virus_e11-11-2014). One infected person or animal can spread the EVD infection in crowded location(s) such that outbreaks thereafter can assume pandemicity. Unless the invasion of EVD is controlled by all-round preparedness, EVD in India, if it some how gets introduced, could rapidly become a pandemic. Preventive measures against the emerging Zika virus disease (ZVD) are being developed using those enunciated against the EVD as the model (Currie et al., 2016) .
In view of the EVD outbreaks and Ebola virus emerging as a potent bioweapon in recent years the 104
Sushil Kumar et al. research on various aspects of the EVD has been growing steadily, internationally. In the present article, some of the important information about the Ebola virus and EVD described in the current scientific literature has been summarized and discussed to serve as introduction on the subject, with the hope that it will spur greater interest and some research activity on EVD in India, latter especially in the areas of EVD rapid diagnosis, therapeutics and vaccines and other logistics of EVD control.
Ebola Virus Characteristics

Taxonomy, Morphology and Structure
Ebola belongs to the order mononegavirales that comprises of viruses, in which the genome consists of non-segmented (single) negative strand RNA (Kuhn et al., 2010; Li and Chen 2014 ; International Committee on Taxonomy 2013). Four families, having a common ancestor, make the order mononegavirales: Filoviridae (examplified by the ebola virus), Rhabdoviridae (includes the rabies virus), Paramyxoviridae (viruses that cause mumps and measles) and Bornaviridae (that cause disease in horses and other mammalian animals). Besides ebola, the other filoviral genera are Marburg virus and Cueva virus. Marburg virus causes a haemorrhagic disease in humans different from EVD. Ebola and Marburg viruses are highly virulent (perhaps most virulent) pathogens such that they can cause death in humans in 6 to 16 days from infection (Mahanty and Bray 2004; Macleod 2010; Leroy et al., 2011a, b; Funk and Kumar 2015) . Unlike Marburg virus, Ebola is not called a hemorrhagic fever virus since EVD patients develop bleeding rarely, usually in the terminal phase and not earlier (Fowler et al., 2014) . Filoviruses are believed to have originated from an ancestor about 16-23 million years ago, coinciding with the origin of great apes (Taylor et al., 2014) . There is evidence that new strains (species) of virus emerge during passage in animals and humans (Kuhn et al., 2014) . Ebola virions are tubular, generally 80 nM in diameter and 800 nM in length; however, due to concatamerization some ebola virions may be as long as 14000 nM. They are pleomorphic by being linear, branched, V-shaped or 6-shaped (Sanchez 2001; Acha and Szyfres 2003) . The single, linear, helical and negative sense RNA genome is contained in a nucleocapsid, which is enveloped by another capsid, which in turn is enclosed in a lipid membrane. There are knob-shaped surface projections on the virus, 10nM long and placed 10nM apart as peplomes embedded in the outer surface of the lipid bilayer (Fig. 1A and 2A) . The genus ebola has species, that have different geographical origins and demonstrate 3 to 41% nucleic acid sequence divergence; the species are named after the geographical region of their original identification (Fauci 2014; Kuhn et al., 2014) . The ebola species can be arranged in the following order based on their pathogenicity-cum-virulence: Zaire ebola virus (ZEBOV) > Guinea ebola virus (GEBOV, responsible for the ongoing EVD epidemic in West Africa) > Sudan ebola virus (TAFV) > Reston ebola virus (REBOV, non-pathogenic on humans) (Cheng and Kelly 2014; Spickler 2014) . ZEBOV is the type species and is also referred simply as EBOV. Genetics of differential pathogenecity between EBOV species needs dissection.
Host Range
EVD is a highly contagious zoonotic disease, since all its outbreaks are believed to have started by the transmission of Ebola virus to humans via vertebrate animals; human to human transmissions of Ebola are secondary infections. Humans get infected when they come in contact with blood or body fluids or eat meat of infected animals. Rise in population and deforestation have increased the contact of humans with infected wild life (Bausch and Schwarz 2014; Walsh and Haseeb 2015) . People living in the Ebolaaffected as well as unaffected villages in Africa carry antibodies against Ebola in the range of 1.8 to 21.3 %
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( Leroy et al., 2000) . There is evidence that the present epidemic of EVD in progress in West Africa started in December 2013 as a zoonotic transmission to a two years old boy, in the village Gueckedou in Guinea from Ebola harboring Hypsignathus monstrous and Epomops franqueti bats, infection spread therefrom person to person nosocomially (Table  1; en.m.wikipedia.org/wiki/Ebola_virus_e; 10-11-2014; Baize et al., 2014) . Since bats upon screening were often found to possess Ebola specific antibodies and RNA, bats have been presumed to be the natural reservoir of the virus in Africa; bats get infected with Ebola, lack overt disease and survive (Swanepoel et al., 1996; Reiter et al., 1999; Leroy et al., 2004 and Pourrut et al., 2005 and Peterson et al., 2007; Olival et al., 2013; Baize et al., 2014; Ng et al., 2015) . Presence of Ebola antibodies has also been noted among bat populations in China, Bangladesh and Phillipines (Olival and Hayman 2014) . Ebola antibodies and/or RNA have also been found in the bodies of a variety of non-bat vertebrates, including non-human primates, monkeys, cats, foxes, hogs, antelopes, porcupines and rodents (www.publichealth. gc.ca). It is thought that in forests infested with Ebola infected bats, a variety of co-inhabiting vertebrates catch Ebola infection by coming in contact or eating food (dead or live animals and fruits, flowers and leaves) on which bats have drooled or defecated and which has been similarly contaminated by the body fluids of infected non-bat animals or by eating of meat of the dead or alive Ebola diseased animals. There could be reservoir species of Ebola other than bats. Table 1 gives a list of wild, domesticated and laboratory model animals that get infected with Ebola, but may or may not die of the Ebola disease caused in them. Ebola virus titer is very high in lungs of some infected animals such as pigs which can transmit Ebola virus to other animals via air; however, airborne transmission may not occur in humans since virus titers in lungs are lower than in blood (Weingartl et al., 2013) . In humans there are possibilities of transmission through air over short distance (Wong et al., 2015) . Ebola virus is principally an animalspecific virus which has assumed high level virulence by shifting to new hosts such as humans (Longdon et al., 2015) .
Transmission Among Humans
Ebola enters humans through nose, mouth, eyes, ears, open wounds, cuts and abraded skin or mucous membranes, via direct or indirect contact with the body fluids of a person who has developed the symptoms of EVD or has died from it. The blood, vomit, urine, faeces, sweat, tears, breast milk, semen, mucus, saliva, spit and any other kind of fluid from humans having EVD contains infective Ebola virus. Ebola is present on the skin of EVD patients or their cadavers and there touching them can result in infection. Ebola infection can also result from exposure to saliva from a coughing EVD patients. Contaminated needles and medical equipment if reused without sterilization can cause Ebola infection. Ebola can survive for upto several weeks on eating utensils, bedding, clothing, furniture, door knobs, electrical switches and such materials that may get contaminated by the body fluids and also in water into which body fluids may have been washed into, from the EVD patients (Bibby et al., 2015) . Ebola virus remains in the body of survivors for many months after disease has subsided, especially in immunologically protected organs such as eyes and testicles. Ebola's presence has been recorded in semen of convalescent men at 179 day (average 26 weeks) after recovery (http://www.phac_aspc.ge.ca./lab-bio/ res/pds-ftss/ebpola-eng.php gives references; Rowe et al., 1999; Cardona-Maya et al., 2014; Mate et al., 2015) . Aqueous humor of uveitis eye was found to contain active Ebola viruses, 10 weeks after virus had disappeared from a patient's blood (Varkey et al., 2015) . Transmission from touching the diseased body is possible for at least seven days post-mortem (Prescott et al., 2015) . Virus RNA remains in cadavers for months but naked -ve sense RNA is not infective. Genome sequence analysis of 318 patients in Sierra Leone conclusively demonstrated the a single introduction of Ebola into human population was responsible for the epidemic and that it resulted from human to human transmission (Park et al., 2015) .
Genetics
Genome, Gene Functions, Transcription and Replication
The Ebolavirus genome is a 19 kb single stranded RNA molecule of negative polarity. The seven genes encoded in it lie in the order 3'-Leader-NP-VP35-VP40-GP/sGP-VP30-VP24-L-Trailer-5', as shown in Figure 2A and B. The gene functions are summarized in the Table 2 . GP1,2, VP24, VP40, VP30, VP35, NP and L are not only virion structural proteins but also possess a variety of enzymatic and/or regulatory properties for the processes of virion attachment on host cells, virion entry into host cell cytoplasm and viral multiplication (Fig. 2C) , arrest of antiviral host cell responses, host cell apoptosis and other pathophysiological changes in the host to build a vast reservoir of virus particles for the spread of infection among susceptible animals and humans (Fig. 3) .
The cis sequences contained in Leader and Trailer regions are essential signals for the control of gene transcription, genome replication and packaging of replicated RNA into virus particles (Crary et al., 2003) . Each of the seven genes has its own transcription initiation and termination signals flanking it. The open reading frame of each gene, containing its coding region, is flanked by non-translated sequences of unknown function (Klenk and Feldmann 107 2004; Jasenosky and Kawaoka 2004; Hartlieb and Weissenhorn 2006) . Ebola genome transcription occurs in the host cell cytoplasm after the nucleocapsid of the virion has partially uncoated. In the nucleocapsid, RNA genome is associated with the products of NP, L, VP35 and VP30 genes forming a ribonucleoprotein (RNP) complex. In the RNP, expression begins when the L gene product RNA dependent RNA polymerase (RDRP) transcribes the Leader into a 5'-triphosphate Leader RNA and stops. RDRP restarts at the transcription start signal of NP gene. The initiated NP mRNA is capped. At the NP gene transcription termination site, before NP mRNA is released, the RDRP stutters at a stretch of Us and produces a polyadenylated tail on NP mRNA. Then RDRP moves on to transcribe the gene VP35. Seven genes are transcribed sequentially in the order of their arrangement on Ebola genome. Interestingly, the GP gene transcription results in production of mRNA for three different gene products, namely Pre-sGP (small GP), Pre-GP and Pre-ssGP (small secretary GP), which post-translation get respectively processed into sGP, GP1 and GP2, and ssGP. Normal transcription (bulk) produces mRNA for Pre-sGP, which is the GP gene's primary product (> 70%). Editing in transcription (editing = RDRP reads a template base more than once causing a base addition in the mRNA product) produces Pre-GP (< 25%) and ssGP (minor , ~5%) mRNAs. At the editing prone site, insertion of an additional A residue at the RNA editing site results in mRNA for Pre-GP protein. Likewise, insertion of two A residues produces ssGP mRNA (Volchkov et al., 1995; Sanchez et al., 1996; Mehedi et al., 2011; Mohan et al., 2012; Mehedi et al., 2013; Shabman et al., 2014; Mohan et al., 2015) .
Fig. 2: Caption on next page
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Genes located nearest to the Leader sequence are most transcribed and those near the Trailer sequence are less trancribed. NP is most expressed and the concentration of its protein product determines the switching from gene transcription to genome replication. RDRP replicates the genome by binding to the 3' Leader and moving on to the 5' end Trailer. Replication results in positive strand full length antigenomes. RDRP binds to the 5' Trailer and accomplishes full length transcription/replication of encapsidated antigenomes to produce the negative strand genome copies. The negative single strand RNA genome copies are then encapsidated and packaged into virion progeny particles and released via host cell plasma membrane (Ascenzi et al., 2008; Olejnik et al., 2011; Choi and Croyle 2013) .
EBOV is also dependant on several kinds of Swanepoel et al., (1996) and Reiter et al., (1999) have demonstrated absence of Ebola virus growth in the experimentally inoculated plants of fabaceae, solanaceae, cucurbitaceae and gramineae families and in non-mammalian animals, including a few insects, spider, snail, a few reptiles and a bird host factors for its replication. For example, the host protein eIF5A (eukarytic initiation factor 5A), hypusinated by spermidine (a polyamine) is essential for EBOV replication, via control of the availability of VP30 (a polymerase component) in suffiient quantity (Olsen et al., 2016) . The BCL2 Associated
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Sushil Kumar et al. Athanogene 3 (BAG3) product, an autophagy regulator-chaperone protein, interacts with VP40 and requesters it away from plasma membrance such that the egress of viral particles is counteracted (Liang et al., 2017) . Both host-virus-interactions are targets for therapy development. et al., 2015) . In several species of bats, rodents and marsupials, VP35-, NP-and L-like Ebola genes have been detected. Only in the related species, fossil copies of Ebola genes are often present in syntenous positions; this indicates that interaction between mammals and Ebola has occurred repeatedly (Taylor et al., 2011 and . Ebola genes present in Ebola sensitive species may be in their wild type or mutant state. The Ebola tolerant phenotype of Ebola reservoir bat species (Leroy et al., 2005; Ng et al., 2015) may be because of the animal genome borne Ebola gene products negatively complement proteins specified by the infecting Ebola virus.
Ebola genome is prone to high mutation rate, because its L protein (RDRP) makes errors during genome replication but is not able to correct them. Ebola lacks the proof reading mechanism of DNA polymerases (Liu et al., 2003) . The mutation rate in the Ebola GP gene is estimated as 3.6 x 10 -5 nonsynonymous substitutions/site/year (Suzuki and Gojobori 1997) . For the whole genome, mutation rate in different Ebola species is known to vary from 0.45 x 10 -4 to 1.25 x 10 -3 nucleotide substitutions/site/year (Park et al., 2015) . The average molecular rate of evolution in the Ebola genus is therefore several orders of magnitude greater (3.5 x 10 4 times) than that in the human nuclear genome (Carroll et al., 2013; Park et al., 2015) . This means that EBOV, in the course of its passages between hosts, perhaps extends its host range and improves its contagiousness. Because of bulk of mutations may be of negative value (non- Analysis of 81 Ebola genome sequences of origin in the recent outbreak in Sierra Leone (West Africa) revealed 341 mutations that were new and not present in previously sequenced EBOVs of origin in central Africa. L, NP and VP24 were the genes in which a majority of mutations were localized (Gire et al., 2014) . Mutation A-82V in GP gene increased Ebola's infectivity towards human cells highly significantly and thus achieved greater adaptibility for humans (Diehl et al., 2016) .
A forward genetics experiment has shown that non-synonymous subsitution mutations in the EBOV GP gene increased Ebola's human cell tropism and decreased tropism towards bat cells, suggesting evolution of increased infectivity against humans in Ebola (Urabanowicz et al., 2016) .
Ebola undergoes mutations not only during animal-to-human and human-to-human transmission, but also during animal-to-animal transmission. EBOV infection in guinea pigs is asymptomatic; infected animals multiply the virus, but are devoid of clinical symptoms. Five and seven time passaging of Ebola in guinea pigs, respectively, led to the development of clinical symptoms and death. Mutations in GP, NP, VP35, VP24 and/or L and not in VP30 and VP40 were observed to be responsible for increase in virulence by repeat passaging of virus in guinea pigs. Significantly, virulence increase was associated with increased rate of editing in GP and mutation at position 26 in VP24 (Subbotina et al., 2010; Dowell et al., 2014) . It is thought that in future when vaccines and treatments against Ebola become available, EBOV may survive by evolving decreased virulence and increased contagiousness. Table 5 120 Sushil Kumar et al.
Ebola Virus x Host Interactions
Biology of Virus Entry Into and Multiplication in Host Cells
Ebola virus present in secretions and excretions of infected animal/human Ebola-diseased enters human host via the mucosal surfaces (in eyelids, lips of mouth, nostrils, ears, anus and man and woman genitals) and injured skin. Dendritic cells, macrophages and monocytes (of the mononuclear phagocytic system) are the initial targets of Ebola virus entry and for its multiplication. Subsequently, multiple mechanisms, including migration of infected mononuclear phagocytic cells and release of virions into lymphoid system or blood stream, make the infection systemic. Besides the macrophages, monocytes and dendritic cells, hepatocytes, adrenal cortical cells, fibroblasts, endothelial and epithelial cells of various tissues and organs of host body get infected and fatal infection results from necrosis of infected cells (Mahanty and Bray 2004; Feldmann and Geisbert 2011; Olejnik et al., 2011; Chiappelli et al., 2015; de La Vega et al., 2015) .
Ebola virus replication cycle is shown diagrammatically in the Figure 2C . To gain entry into host cell, virion attaches to the receptors present on the surface of the susceptible host cell via its glycoprotein GP1 present on virus envelope. The interaction of phosphatidylserine present on cell membrane and Ebola virion facilitates this process. Host cells demonstrate differences in the spectrum of Ebola receptors present on their surface. Some of the receptors are: folate receptor-á, C-type lectin family proteins such as DC-SIGN, L-SIGN, L SECT, hMGL, and asialo-glycoprotein, T-cell immunoglobulin (Volchkov et al., 1998; Weissenhorn et al., 1998; Chan et al., 2001; Takada et al., 2003; Marzi et al., 2006a and 2006b; Hunt et al., 2011; Lennemann et al., 2014; Cheng et al., 2015; Rhein and Maury 2015) . Following attachment, virion gets enclosed into a ruffle/bleb (macropinosome) of plasma membrane. Macropinocytosis internalizes the macropinosome (Hunt et al., 2011) , which is then trafficked to the endolysosomal pathway (Bhattacharyya et al., 2012; Miller and Chandran 2012; Nanbo et al., 2010; Saeed et al., 2010; Carette et al., 2011) . Under the acidic environment of endosome, cysteine proteases cathespin-B and -L and other proteases cleave GP1
such that its aminoterminal domain gets exposed, which is ligand for the intracellular receptor NiemannPick Type C1 (NPC1 = Cholesterol transporter) protein of host plasma membrane. NPC1 and GP1 interaction is essential for the viral and host plasma membrane fusion (Carette et al., 2011; Cote et al., 2011; Miller and Chandran 2012; Herbert et al., 2015; Spence et al., 2016) . Conformational changes in GP2 (a class1 viral fusion protein) unmask its fusogenic domain (45aa loop near to N-terminus) and also such domains in the endosomal membrane such that fusion occurs between them on their interaction (Chandran et al., 2005; Hood et al., 2010; Gregory et al., 2011; Miller and Chandran 2012) . As a consequence the ribonucleocapsid of virion is released into host cell cytoplasm.
In the host cell cytoplasm, the virus genome which is a part of somewhat relaxed ribonucleocapsid, serves as a template for the sequential transcription of all the seven genes, into monocistronic mRNAs, which are capped and polyadenylated and translated to produce viral proteins. When enough of NP has been produced, genome replication starts. Nascent +ive (antigenome) and -ive (genome) RNAs assemble into their nucleocapsids. VP35 chaperones NP to replication complex, helps NP to coil arround the progeny RNA and form the nucleocapsid shell (Kirchdoerfer et al., 2015; Leung et al., 2015) . In the self assembly process of encapsidation, RNA-NP interaction makes RNA helicoidal and allows interaction with VP30, VP35 and L proteins (Watanabe et al., 2006 and Bharat et al., 2012) . Termination of the replication phase and onset of virion assembly and egress phase is controlled by VP24. Virus budding and egress involves the viral proteins VP24, VP40 and GP and host protein machinery, including endosomal sorting complex required for transport (ESCRT) (Han et al., 2003; Jasenosky and Kawaoka 2004; Licata et al., 2004; Watanabe et al., 2007) . Nucleocapsids arrive at VP40 and GP containing multivacuolar bodies at the plasma membrane for their constitution as virions and egress (Dolnik et al., 2004; Hartlieb and Weissenhorn 2006; Liu et al., 2010) . Virus particle formation is aided by phosphatidyl serine at the plasma membrane (Soni et al., 2013; Soni and Stahelin 2014) . Egress is accompanied by virus particles acquiring GP studded cellular plasma membrane lipid bilayer linked to ribonucleocapsid by the matrix proteins VP24 and VP40 (Klenk and Feldmann 2004; Chandran et al., 2005; Manicassamy et al., 2005; Marzi et al., 2006a, b; Hoenen et al., 2010; Liu et al., 2010; Olejnik et al., 2011; Adu-Gyamfi et al., 2013) .
The variation in the incubation period of 2 to 21/ 23 days, before symptoms of Ebola disease development start to appear, is thought to depend on the size and route of virus inoculum and host genetic factors that determine the degree of success in mounting the innate adaptive response against the virus multiplication. In the survivors of Ebola virus disease, the viral titer from initial stages onwards is 100 to 1000 fold lower than non-survivors. The patients nearing death may have 10 billion virus particles in their body.
In patients recovering from EVD, replicating viral RNAs are present in lower and upper respiratory tracts for several to many days, after RNA is no longer detectable in blood plasma (Biava et al., 2017) . This suggests that though the tissues of all body organs get infected, there is major role of lung tissues in pathogenesis and raises the possibility of transmission via exhaled air.
Host Pathophysiology
Highly virulent property of Ebolavirus is responsible for the development of severely sick pathophysiology of deadly consequences in humans. Pathophysiology of fatal EVD involves more or less the entire body of the patient and several aspects of it remain to be understood. Much of the information about EVD pathogenesis has been gained from case reports of the diseased persons of the previous and current EVD outbreaks and laboratory studies on animal model systems. Some of the important turning points in the progression of fatal EVD pathogenesis are: Rapid replication of Ebola virus and correlated impairment of host's innate and adaptive antiviral immune response(s); Invasion of body organs via lymph and blood stream and cellular/tissue necrosis in them; Host's pro-inflammatory response to virus/cellular debris; and collapse of vascular system, hemmorrhaging, multi-organ failure, drop in blood pressure, hypovolemic shock and death. These broad features of the human EVD pathophysiology are diagrammed in Fig. 3 and aspect-wise discussed below in some detail.
Innate Immune Response and Its Blockage by Ebolavirus
Interferons Ramanan et al., 2011; Kuhl and Pohlmann 2012; Messaoudi et al., 2015) . VP35 blocks IFN production by suppressing RLR activation, inhibition of IRF-3 phosphorylation and sumoylation of IRF-7 (Basler et al., 2003; Basler and Palse 2004; Cardenas et al., 2006; Chang et al., 2009; Prins et al., 2009; Luthra et al., 2013) . VP24 blocks ISGs expression by blocking nuclear transport of STAT-1 (Reid et al., 2006; Dolnik et al., 2008; Mateo et al., 2009 and 2011; Daugherty and Malik 2014; van Hook 2014; Xu et al., 2014) . GP2 of GP1, 2 mislocalizes tethrin in plasma membrane such that tethrin cannot interfere with the VP40 based release of Ebola virions (Kaletsky et al., 2009; Radoshitzky et al., 2010 and 2011; Kuhl and Phlmann 2012; Audit and Kobinger 2014) .
Adaptive Immune Response and its Abrogation by Ebola
White blood cells in the form of neutrophils and lymphocytes-Natural killer (NK) cells, B-cells and T-cells-comprise the components of adaptive immune response. Dendritic cell (DC) functions bridge the innate and adaptive immune systems. Presentation of pathogen antigens by DCs to T-cells starts a cascade that activates T-cell transcription factors
NFAT (Nuclear factor of activated T cells) and AP (Activating protein)-1. NFAT and AP-1 induce transcription of anti-pathogen proteins in T-cells. However, Ebola infected DCs are deficient in performing their T-cell activating function. This leads to T-cell apoptosis (Reid et al., 2007; Hartman et al., 2008a and b; Jin et al., 2010; Daugherty and Malik 2014; van Hook 2014; Xu et al., 2014) . sGP disables neutrophils; the absence of neutrophil function allows extensive viral replication (Leroy et al., 2011a and b; Mohan et al., 2012) . sGP soaks any anti-Ebola (anti-GP1.2) IgG and IgM antibodies synthesized by Bcells and arrests movement of B-cells. Altogether, host's adaptive immune system gets compromised and Ebola is able to invade body organs (Geisbert et al., 2000 and 2003a, b; Baize et al., 2002; Hartman et al., 2008; Jin et al., 2010; Leroy et al., 2011a and b; .
Additional Cytoplasmic Effects of Ebola Virus Proteins
Besides suppressing host's immune system, Ebola proteins impair the host by several additional means.
VP35 interacts with the enzymes of SUMOylation such as SUMO F 2 enzyme Ubc 9 and appropriates the SUMOylation system (Chang et al., 2009) . VP35 protects the cellular translational machinery from shutdown by the action of IFN and double-stranded RNA activated Protein kinase (PK)-R (PKR) (Williams 1999; Feng et al., 2007; Schumann et al., 2009; Escudero-Perez et al., 2014; Shuchman 2014 ). VP35 together with VP30 and VP40 suppresses the RNAi silencing mechanism, by interacting with TRBT (Trans-activation response RNA binding) and PACT (PKR activating) proteins that are parts of the host's RISC (RNA induced silencing complex) system (Haasnoot et al., 2007; Fabozzi et al., 2011) . GP causes deficiency of integrins and thereby, potentiates breakdown of extracellular/ intercellular matrix which leads to injury to blood vessels, consequently leading to the damage of organs (Francica et al., 2010) . GP bound macrophages and DCs produce/ release soluble proteins/ tissue factor(s) that immuno-modulate cell / tissue expression, which in turn causes dysfunctional bleeding and clotting (Ansari 2014; Goeijenbier et al., 2014; Burd 2015; Chiappelli et al., 2015) . GP1.2 expression causes many host miRNAs to be differentially expressed and several of them mediate the host cell damage (Sheng et al., 2014 ).
Host's Pro-Inflammatory Response to Ebolavirus Multiplication Results in Failure of Organ Functions and Death
Macrophages (developed monocytic white blood cells) are present in tissues of most human body organs (Gordon et al., 2014) . Initially, Ebolavirus multiplies in DCs, monocytes and macrophages at the place of infection. Subsequently, movement of infected macrophages, via blood stream, spreads the infection to sister cells in various organs. From there, Ebolavirus infection gets distributed to cells of other tissues colocated with macrophages in different organs. While systemic infection through macrophages is advancing and Ebolavirus titer is rising, host cells express an aberrant pro-inflammatory response that has mortal consequence. The process leads to abundant release of chemokine proteins and reactive oxygen and nitrogen species. The kinds of cytokines produced are: Interferons, Interlukin (IL)-1β and several other ILs, Tumor necrosis factor (TNF)-alpha, CCL4 (a macrophage inflammatory protein), CCL3 and CXCL10 (a IFN-ϒ induced protein), chemotactic proteins such as Eotaxin and MCP (Monocyte chemotactic protein)-1 and growth related Oncogenealpha (Ksiazek et al., 1999; Villinger et al., 1999; Geisbert et al., 2003; Mahanty et al., 2003; Mahanty and Bray 2004; Sanchez et al., 2004; Wauquier et al., 2009 and 2010; Ansari 2014; Burd 2015) . This cytokine storm results in a variety of pathogenic effects. Necrosis occurs in liver, spleen, lymph nodes, thymus, pancreas, kidneys, lungs and gonads and there is extensive fluid loss. Hepatocellular necrosis leads to deficiency of coagulation and other plasma proteins. There is breakdown of endothelial barrier, leakage of blood into tissues, massive hemorrhage and drop in blood pressure. Arterioles develop small blood clots (disseminated intravascular coagulation, DIC). These, together with induction of general coagulopathy contribute to thrombocytopenia. Death follows development of hypovolemic shock syndrome (Mahanty et al., 2003; Mahanty and Bray 2004; Reed et al., 2004; Ruf 2004; Sanchez et al., 2004; Wauquier et al., 2009 and 2010; Kuhl and Pohlmann 2012; Fletcher et al., 2014) .
Course of Ebola-pathogenesis in Survivors
In the various outbreaks of EVD recorded in Central and Western Africa, about 25 to 75 % of the patients have been observed to survive the Ebolavirus infection. Precise knowledge as to why and how some EVD patients survive remains to be known. It is thought that the outcome of EVD may depend on the (a) genotype of the virus, (b) type, number and location of initially infected cells, (c) previously acquired immunity to Ebola or heterologous virus(es), and (d) genetic tolerance/ resistance to Ebola, in the infected person. There is evidence that survivors (a) possess activated B-and T-cells and virus specific antibodies, despite lymphopenia, (b) generate much diluted proinflammatory response, and therefore, occurrence of necrosis in their organs is limited/ avoided, and (c) do not suffer significant vascular damage (Ruf 2004; Wauquier et al., 2009 and 2010; Fletcher et al., 2014; McElroy et al., 2015; Chiappelli et al., 2015) . Detailed knowledge about factors that lead to survival against EVD is required to develop therapies against the disease.
A deep understanding of Ebola disease pathogenesis in terms of the interactions between genes/proteins of Ebola with those of the human host is required for designing and constructing the most logical pre-and post-recombinant vectored vaccines and for discovering effective therapeutics, especially those that do not require parenteral administration.
Host Alleles that Protect Against Ebola Disease
In the course of Ebola outbreaks in Central and Western Africa, a general observation is that people responded to Ebola differentially. Whereas many developed severe symptoms and died, some showed symptoms of the disease but survived and a third group resisted the disease completely (Ascenzi et al., 2008; Leroy et al., 2011a, b; Chang et al., 2013a, b; Burd 2015) . This indicated that there may be some human gene/s allele(s) that made people resistant to Ebola infection/disease. Mutant forms of human genes HLA-B (Human Leukocyte Antigen-B) called Bx07 and Bx14 have been observed to render their bearers survive the Ebola infection. Contrari-wise the alleles Bx67 and Bx15 make their bearers susceptible to Ebola infection leading to their death. It has been shown that the NP and VP35 proteins of the virus bind tightly to Bx07 gene product as compared to Bx67 protein . Thus, there may be depletion of the functional NP and VP35 proteins in Bx07 Bx07 persons.
Skin cells from Niemann-Pick C1 (NPC1) gene mutant human homozygotes were observed to be resistant to in vitro Ebola virus infection (Carette et al., 2011; Cote et al., 2011; Bellan et al., 2014) . NPC1 non-function causes in the mutants a neurodegenerative disorder due to defect in cholesterol transport and related functions. It is known that mitochondria have intimate interaction with nuclear encoded NPC1. This indicates that there could be human mitochondrial haplotypes who may tolerate Ebola infection (Bellan et al., 2014) . Mice mutated in their NPC1 gene have been observed to resist Ebola infection (Cote et al., 2011; Herbert et al., 2015; Ng et al., 2015) .
A study related with response of Ebola infection in recombinant inbred lines of mice revealed that mice lines were of three types, those that resisted Ebola, another group that were susceptible to Ebola leading to death in mice and a group in which Ebola infection was largely asymptomatic. Among the resistant mice, alleles of TIE1 and TEK genes were present such that the mice bearing them had a relatively more active coagulation pathway due to better regulation of fluid passage in blood vessels (Rasmussen et al., 2014) .
Discovery of Ebola resisting genes and mechanism of their action will be greatly valuable in the design of vaccines and discovery of new therapeutics. For example, an inhibitor of NPC1 has been discovered (Cote et al., 2011) .
Symptoms and Diagnosis of Ebola Virus Disease
Common Symptoms
The incubation period (or the time period from infection to appearance of symptoms) of Ebola infection in humans is 2 to 21 days, but it could be longer (Haas 2014). Usually, EVD symptoms begin to appear 5-10 days after infection. The symptoms are mild in the begining. but they rapidly become severe and upto 90% of the patients can die 7-10 days after the onset of symptoms. A list of symptoms that may progressively appear in the EVD patients and corresponding laboratory test indications are shown in Table 3 . The first symptoms are non-specific and are similar to those of dysentry and influenza, lassa, malaria, meningitis or typhoid fever. They consist of fever (39-40 degree Celsius), fatigue, headache, nausea, soar throat and abdominal/muscle pain. Subsequently a variety of problems appear, including vomiting and diarrhea (that cause acute volume depletion and hypotension), cough, shortness of breath and chest pain, prostration, oedema, confusion and delirium. These are followed by multiple organ failure. Death is preceeded by hemorrhages (Fig. 1B) , mucosal hemorrhages and visceral hemorrhage effusionsdiffuse coagulopathy, convulsions and shock. Laboratory findings in the initial stages show low white blood cell count and in later stages, low platelet count (50-100,000/microliter), high levels of liver enzymes (two to three times of normal) and split fibrin products (Feldmann and Geisbert 2011; Kortepeter et al., 2011; Hunt 2014; Hunt et al., 2011) . Ebola virus infections can also be mild or asymptomatic. Elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the proportion AST : ALT : : 15 : 1 on days 6 to 8 from appearance of symptoms indicates fatal EVD. On the other hand AST : ALT : : 5 : 1 is indicative of survival Kortepeter et al., 2011; Hunt 2014; Hunt et al., 2011) . Severe diarrhoea related hypoperfusion produced metabolic acidosis and hypokalemia in patients with fatal EVD can lead to serum levels as low as 2 m Eq. L -1 (Fowler et al., 2014) . Some characteristics of convalscing patients are also summarized in the Table  3 . Survivors of EVD often suffer from long term physical and mental health complications, chronic pancreatitis, colicky abdominal pain, such as musculoskeletal pain, tremors, memory loss, depression, headaches, tinnitus, hearing loss uveitis, photophobia, conjunctivitis and loss of eye sight, arising from damage to brain, eyes and joints, body parts poorly accessed by immune system (Scott et al., 2016; Vetter et al., 2016) .
Diagnosis
Clinical diagnosis of Ebola infection is safely and most reliably accomplished by the use of ready-made kits of standardized reverse transcriptase polymerase chain reaction (RT-PCR) , which detects the presence Ebola RNA in blood or plasma and by using enzyme linked immunosorbent assay (ELISA), which detects specific viral protein/antigen in serum, plasma or whole blood (Table 4) . Biosafety level 4 conditions are used while performing the tests. The tests are performed on persons who have a history of presence among EVD patients or in the area of outbreak in preceeding 23 days, within 0-2 days of the apperance of initial symptoms, especially rise in body temperature. False positive or negative results are avoided by conduct of ELISA or other test(s) and RT-PCR tests on the suspected patients of EVD. RT-PCR of urine and breast milk of lactating mothers and semen of men recovering from Ebola infection has been recommended (Bausch et al., 2007; Moreau et al., 2015) . New automated RT-PCR blood tests, quick and easy to perform have proved accurate in field applications (Semper et al., 2016; Ahrberg et al., 2016) . A 37 minutes test detects Ebola RNA load from finger prick in diseased and semen, breast milk and eye fluids in post-recovery patients (Ahrberg et al., 2016) .
Recently, three rapid point-of-care tests have been described, which complement the RT-PCR test (Table 4 ). The dipstick immunoassay is performed by placing a finger-pricked drop of blood on a paper strip which detects in the blood presence of VP40 matrix protein of Ebola virus as a band. The test has been shown to be 100% sensitive and 92% specific, using RT-PCR test as the standard. The kit needs to be maintained at 4 o C, otherwise no other external instrumentation is necessary (Broadhurst et al., 2015) . Another strip-test involves magnetic nanoparticlebased immunochromatography. The reaction of antibody against glyoprotein GP of Ebolavirus, that is coated on the paper probe, with antigen present in the blood sample is visualized as colour change on the strip (Duan et al., 2015) . A colour coded paper strip diagnosis based on multiplex lateral flow technology simultaneously detects Ebola, Yellow fever and Dengue virus infection(s) in persons having fever (initial symptoms of Ebola and other diseases). In this test, yet to be commercialized, antibodies to viruses are conjugated to silver nanoparticles of different sizes and electrostatically absorbed to paper in different regions of paper strip. Upon application of test serum, virus-wise antigen-antibody (NSI protein of Yellow fever and Dengue viruses and GP of Ebola virus) interaction(s) allow development of red colour for Ebola, orange for Yellow fever and green for Dengue, in their respective areas on paper strip. This 10 min test will cost as much as a pregnancy test (~Rs. 150), after which it is designed (Yen et al., 2015) . Recently, Cai et al., (2015) have reported an optofluidic analysis system that detects presence of 0.2 plaque forming units/mL in finger pricked blood sample in under ten minutes at point of care. This test is as sensitive as the RT-PCR, the Gold standard test for EVD.
Several point-of-care affordable diagnostic tests based on metagenomic analysis of virus genomes present in samples such as blood, plasma, body tissue, nasal excretions and or stool are in offing. ViroCap and VirCapSeq-VERT are highly sensitive virome capture procedures, based on metagenomic shotgun sequencing approach, that have been respectively described by Wylie et al. (2015) and Briess et al. (2015) . These procedures have both diagnostic and research applications. Besides identifying the presence of any of the 207 viruses of 34 families of RNA and DNA viruses known to infect vertebrate animals and humans, the tests detect known and unknown variants/ subspecies of viruses, withput prior knowledge about their presence in clinical samples. The present cost of such a diagnostic test is about US$40 (~Rs. 2500). Greninger et al. (2015) have reported a point-of-care test, based on nanopore sequencing of viral genome present in high viral titer samples of blood, plasma or tissue from patients combined with MetaPORE realtime bioinformatics analysis, whose results become available in about 6h. Faye et al. (2015) have developed a mobile kit that detects ebola RNA in oral swabs of infected persons in 30 min under high temperature environment of 42 o C using a rapid recombinase polymerase amplification.
A transcriptomic diagnostic blood test has been developed by Liu et al. (2017) which predicts whether patients with Ebola virus disease will survive or die. In this test, abundant accumulation of human m RNAs from internal organs such as liver is indicative of death and increased accumulation of transcripts from NK (natural killer) cells is predictive of survival.
Briefly, a fairly good progress is being made in developing reliable and affordable diagnosis tests for Ebola virus disease, which can be used in the field as well as in hospital laboratories.
Sterilization of Materials Contaminated with Ebola Virus
Ebolavirus retains its infectivity at room temperature for several days. To stop spread of Ebola infection, it is impotant to sterilize surfaces and materials contaminated with Ebola (Ebola containing exudates from EVD patients). Ultra violet light (UV) inactivates Ebola virions. UV-emitting tubes, lamps and torches are available to UV-light even the whole rooms to sterilize Ebola containing surfaces. Gamma rays (1.2 x 10 6 rads) also inactivate Ebola virions present in liquid or solid materials; Gamma cells are available to irradiate materials. Boiling of materials for five minutes or exposing of materials to 60 degree Celsius for 30 min are also effective in inactivating Ebola. Diluted ethyl/methyl alcohol (10%), acetic acid (3%), chlorine solution (5%), Sodium hypochlorite (5.25%) and gluteraldehyde (1%) are readily available Ebola disinfectants. Ether, Sodium deoxycholate, β-propiolactones, 1,5-iodonapthylazide, guanidium isothyocynate also render Ebola virions in-infective (Burd 2015; Chiappelli et al., 2015) .
Measures to Counter Ebola Virus Disease
The reservoirs of Ebola virus variants, persistent in wild animal hosts, in areas of their endemicity, and acts of bioterrorism can be the cause of outbreaks of EVD in future. Secondary infections from Ebola infected foreign visitors/travellers could make such outbreaks pandemic. Counter measures against EVD are urgently required to stem the ongoing outbreak in West Africa and any future outbreak(s) within or outside of the region of common existence of Ebolavirus. EVD would be best controlled by a single dose vaccination not requiring a booster dose and providing protection for as long as ten years. The other course is to counter EVD with antiviral therapeutics. Both vaccines and therapeutics are desired that can ward against Ebola infection and/or cure the EVD. Intensive efforts have been in progress in both the directions.
Anti-Ebola Vaccines
The general idea underlying the ongoing anti-Ebola vaccine development programme is to overexpress, in the vaccinated persons, Ebola proteins such as GP, VP40 and NP that are known to themselves cause no serious disease. GP is present on the surface of the virus and is highly immunogenic, but evolves faster than other genes (Jun et al., 2015) . The GP gene, GP and VP40 or GP and NP genes are recombinationally inserted into the genomes of viruses that do not cause serious disease or produce no or only minor side effects. GP, VP40 and NP proteins synthesized from Ebola vaccine virus genomes serve as small antigens to incite effective and B and T cell mediated antiEbola immunity (Becquart et al., 2014; McElroy et al., 2015) . An Ebola virus whole genome (minus VP30) vaccine to prime host's immune system against many proteins of virus is also under testing. It is desired that the design of vaccines should be such that they can be produced readily in large quantities.There are several anti-Ebola vaccines under development. A few of these mentioned below have reached advanced clinical testing on human volunteers, following their effectivity tests on non human primates (Table 5) .
VSV ∆G/EBOV GP or rVSV-ZEBOV vaccine: Presently, this is the most promising anti-Ebola vaccine. The Zaire Ebola GP gene is added on to the replication competent genome of Vesicular Stomatitis Virus (VSV, a rabies family zoonotic virus infective on insects, cattle, horse and pigs causing flu-like disease in humans) incapacitated for disease causation by deletion of its own glycoprotein gene. Non-human primates, both native and previously VSV vaccinated, were completely protected by intramuscular VSV ∆G/EBOV GP vaccination, against challenge of lethal dose of EBOV four weeks after vaccination. Post vaccination, animals did not develop fever or any other adverse effect. It proved safe and effective on human volunteers and phase III trial is in progress (Marzi et al., 2011 (Marzi et al., , 2013 (Marzi et al., , 2015a Marzi and Feldmann 2014; Regules et al., 2015) . Recent final analysis of a ring vaccination in Guinea (West Africa) has indicated that rVSV-ZEBOV is effective and safe in preventing EVD at population level. Delivered via ring vaccination strategy, the vaccine is able to control EVD outbreak (Henao-Resrepo et al., 2015 and .
Ad-CAG opt ZGP and HPIV3/EboGP: These vaccines are another promising first line defence against EVD. In the Ad-CAG opt ZGP the vector is replication incompetent Adenovirus serotype 5 genome into which is inserted the ZEBOV GP gene optimized for over-expression in human cells. In HPIV3/EboGP, the vector for GP gene is human parainfluenza virus type 3. A single nasal spray of formulated either vaccine gave long lasting protection to non-human primates. The vaccine induced strong response in CD8+ and CD4+ T cells and Ebola GP specific antibodies in mucosa as well as systemically (Choi and Croyle 2013; Choi et al., 2014; Meyer et al., 2015) . When available for human use, this type of non-injectable vaccines will have greater affordability due to simplification of transport, storage and administration of vaccine.
Ch-Ad3-EBOZ vaccine: Several versions of this vaccine are under development; they all have replication incompetent Chimpanzee Adenovirus type 3 genome as the vector, but vary in composition of the GP gene insert: GP of Zaire Ebola, GPs of Zaire and Sudan Ebola or GP of Marburg virus. These are used monovalently as well as bivalently (Zaire + Sudan and Marburg GP vaccines together). Intramuscular administration of a dose of Ch-Ad3-EBOZ followed by a booster dose of pox virus-GP vaccine eight weeks later gave full protection, as observed at 10 months after initial vaccination, in non-human primates (Kibuuka et al., 2014; Ledgerwood et al., 2014; O'Brien et al., 2014; Stanley et al., 2014; Sarwar et al., 2015) .Other booster vaccines to complement ChAd3 based vaccines are under development (Rampling et al., 2015) .
VP30 minus whole genome vaccine: This vaccine uses whole Ebola virus from which VP30
gene has been deleted. The virus particles are inactivated with hydrogen peroxide. One dose of the vaccine protected cyanomolgous monkeys against the fatal dose of Ebola virus (Marzi et al., 2015a and 2015b) .
More than one kind of vaccine/s referred to here (and in Table 5 ) that are undergoing clinical trials in Africa are expected to be used and commercialized in the period of ongoing West Africa outbreak.
To control EVD outbreaks due to zoonotic transmission of Ebola virus to humans, development of animal species-specific anti-Ebola selfdisseminating vaccine(s) is in progress. Animal species specific cytomegaloviruses, that have little or no effect on human health, are being altered to carry Ebola genes such as GP. Such vaccines are expected to immunize animals in the wild against Ebola virus infection ( Murphy et al., 2016; Marzi et al., 2016) .
Anti-Ebola Therapeutics
Presently, there is no specific treatment or drug for EVD that is proven to be safe and effective. Several types of treatments and medicines are under development; Tables 5 and 6 give a list of 138 chemicals/materials that are receiving attention. The thirty four putative cures of EVD included in Table 5 are those known to possess properties to antagonise the Ebola virions and/or expression products of Ebola virus genome, essential for the entry of virions into host cell and virus multiplication in host tissues and/or the virus infection induced host processes, leading to vascular damage and failure of multiple organs in host's body. Some of these are currently in different stages of clinical testing and several have been permitted by WHO for use on EVD patients on compassionate ground. The chemical structures of 16 of the putative anti-Ebola drugs mentioned in the Table 5 The table 6 lists 96 small molecules and γ-interferon, already in use as approved drugs for a variety of non-EVD human ailments, which have been identified as possible medicines for EVD, singly or in combination. There is experimental evidence that these drugs interfere with entry of Ebola into host cells and relieve some symptoms of EVD in model animals. From the list in Table 6 , several compounds have entered into clinical trials for their use to cure EVD (www.who.int/ medicines/emp_ebola_q as/en/).
Among the six EVD-treatments (convalescent serum, DZNep, F4-6, Melatonin and Z Mapp and E4+E10 monoclonal antibodies) whose properties are summarized in Table 5 , most promising appear to be Z Mapp alone, Z Mapp in combination with DZNep or interferon α and Z Mapp combined with convalescent serum; these require refrigeration and are administered through injections. Non-human primates that received Z Mapp five days after the lethal dose challenge of Ebola virus were found to be fully protected (Qiu et al., 2014) . These treatments have been prioritized for clinical trial. However, a subsequent study has raised doubts about the efficacy of Z Mapp. Kugelman et al., (2015) observed that animals treated with MB-003, a Z Mapp-like antibody cocktail one or two days after Ebola infection, developed mutants of virus resistant to antibodies and succumbed to infection. However, single or combination of specific Ebola neutralizing antibodies isolated from the blood of EVD survivors are proving to be an effective treatment against infection by Bundibugyo, Zaire and Sudan Ebola virus (Burnholdt et al., 2016; Corti et al., 2016; Flyak et al., 2016) . Antibodies from filovirus patients collected 1-14 years after the primary disease have been observed to provide protections against filoviruses in general, including Ebola (Natesan, et al., 2016) . The antibody called mAb114 has been shown to completely protect Rhesus monkeys from lethal Zaire Ebola infection, when delivered intravenously for three consecutive days as late as five days after infection. Its protective action resulted from its ability to interact with receptor binding domain of the Ebola glycoprotein (Corti et al., 2016; Misasi et al., 2016) .
Another group of compounds that hold promise are the drugs of choice against heterologous viral diseases, which demonstrate pronounced anti-Ebola activity. Antivirals BCX4430, GS-5734, Brincidofavir and Favipiravir (Table 5) are also prioritized candidates for clinical trials against EVD; these are stable at room temperature and can be given orally. Another class of drugs receiving impetus for further testing are TKM-Ebola types and AVI-7537, RNAs antiparallel to specific Ebola essential gene mRNAs leading to loss of function of the latter and arrest of Ebola multiplication (Table 5) . Blocking of human calcium signalling pathway, dependent on STIM1 and ORAI1 genes, that is essential for virus escape/ budding from host cells, by compounds such as 5D
(5, N-[2, 2, 2-trichloro-1-(2-napthylamino)ethyl]-2 formamide) has been proposed as a potent therapeutic for EVD. Search for potent ORA1 is in progress (Han et al., 2015) .
Re-purposing tests on thousands of drugs have revealed that compounds with diverse mode of action on human body (Table 6) , variously prescribed for treatment of infectious diseases, disorders of different organs of body, cancers and depression, possess antiEbola activity (Litterman et al., 2015) . They offer possibilities of combinatorial usage to harvest their synergism against Ebola. In the first instance, Azithromycin (antibacterial), Sunitinib (tyrosine kinase inhibitor), Amiodarone (Na + channel blocker), Clomiphene (estrogen receptor modulator), Chloroquine (antimalarial), Bepridil (Calcium channel blocker) and Sertraline (serotonin uptake inhibitor) are being taken up/ recommended for clinical testing against EVD (www.who.int/medicines/emp_ebola_q as/en/; Johansen et al., 2015) . Low doses of Imatinib, a drug related to Sunitinib, stimulate the bone marrow to produce more of neutrophils and macrophages to resist infections (Napier et al., 2015) . Patients given the generic statin drug atorvastatin (40 mg/day) and the angiotensin receptor blocker irbesartan (150 mg/ day) survived EVD 100% (Opal et al., 2015) . The treatment restored the endothelial barrier integrity.
The complementary approaches of designing and re-purposing are bound to yield drug(s) suitable for pre-and post-infection, respectively, to protect against Ebola infection and treat EVD. The experimental observations on re-purposing of medicines summarized in Table 6 and corresponding results of re-purposing of approved and experimental drugs show that a minimum of 43 (perhaps hundreds) of host genome coded functions interact with one or more of nine proteins coded by Ebola genome (Cheng et al., 2015; Veljkovic et al., 2015) . Study of Ebola infection in host cells or whole organisms in the presence of Ebola virus inhibiting compounds is expected to reveal the roles that various host genes play in Ebola virus biology.
Life Saving Supportive Care
Until vaccine and medicine based therapies for EVD become available, supportive medical care, which nurses patients to limit intensity of disease in his/her body, remains the main treatment. The role of experimental therapies (such as Z Mapp, BCX4430, Favipiravir, is not yet firmly established, although their compassionate use has been in vogue. Fig. 6 gives a profile of the currently available, experience based, supportive care treatments of EVD. Supportive treatment essentially consists of ensuring that patient's body maintains fluid volume, balance of electrolytes, oxygen status, blood pressure and kidney function (Hunt et al., 2015) . It has been noted that the EVD patients who start to receive supportive care as soon as the post-incubation period, early symptoms appear have better chances of survival than those who receive the medicinal care in late stages of infection. Recently, Chiappelli et al., (2015) have advised inclusion of Selenium replishment as an element of palliative care. Patients under supportive care take months to recover. Only those are considered as cured in whom virus is found absent from their blood/plasma and other body fluids. The so-called cured/convalescent patients require continued attention for years about one or more of the following medical ailments: psychosis, photophobia, excessive tearing from eyes, sloughing of skin, hairloss, deafness, myelitis, pericardiatis, orchitis, hepatitis and secondary viral, bacterial, fungal or other infections.
Measures to Adopt for Containment of Ongoing Outbreak(S) and Prevention of New Outbreaks of Ebola Virus Disease (EVD)
In the absence of prophylactic vaccines and medicines, EVD is extremely dangerous to human populations on account of the Ebola virus being highly stable and infectious and especially virulent on humans. Chain of person-to-person infection, starting from one Ebola infected human is known to cause EVD outbreaks of large magnitude, such as the present EVD outbreak in West Africa. This outbreak first noted in Guinea in February 2014, has by 31 March 2016, infected over 28639 persons, out of which 11316 have died in Guinea and neighbouring countries Sierra Leone and Liberia. From these countries, EVD got imported into the African countries (Mali, Senegal and Nigeria) and into several countries of Europe (Spain, Italy, France, Britain, Germany, Switzerland, Netherland and Norway) and into Canada and USA. Here (www.msf.org/article/ebola-) are given definition of EVD patients, procedure for identification and quarantining of EVD patients, barrier nursing of EVD patients, disposal of contaminated materials and cadavers and precautions against any deliberate or accidental EVD attack. The concepts are summarized in the Fig. 7 .
EVD Patient
The Ebola virus infection spreads from symptomatic EVD patients. Ebola virus infected persons (patients) develop EVD symptoms after an incubation period of 21/23 days or less. Within one week of the onset of initial EVD symptoms, which are mild and simulate those of several other ailments/infective diseases, the viremia peaks and EVD patient becomes highly infective. Direct contact with such a EVD patient's body or any of his/her secretions/excretions, including the matter liberated into air while coughing and sneezing, can cause infection. Viremic EVD patients who are not bed-ridden spread infection by coming in contact with non-infected in crowded places and to relatives, friends and work colleagues. Upon worsening of EVD symptoms, patient's hospitalization exposes healthcare workers and visitors to hospital to EVD infection transmission. Practice of conventional rituals at the time of funeral of dead EVD transmission is another occasion for extensive EVD transmission (Ebola-RRA-WestAfrica-8April2014. pdf). As a rule of thumb, a person who comes within one metre of living symptomatic EVD patient or cadaver of a person who died of EVD is a suspected case of Ebola infection or EVD patient.
Secure Quarantining of EVD Patients at Health Care Centres/hospitals
EVD can be contained by strictly controlling secondary transmission by identifying and isolating the suspected EVD patients in secure quarantine facilities (Fig. 7) (Roddy et al., 2012; Chowell et al., 2015) . All persons in the geographical region of outbreak who show initial symptoms of EVD and are diagnosed EVD positive will be isolated and treated in specially created wards in identified hospitals. Any traveller who have been to the geographical region of a EVD outbreak over the last three to four weeks period and shows higher than normal body temperature (> 37. from outbreak areas will be observed for development of symptoms over next three to four weeks. Those that develops symptoms will be quarantined, diagnostically tested and confirmed EVD patients will be isolated and treated. The contacts of such patients will be tracked, observed twice daily for body temperature and attended to as per the above EVD patient criterion, ad infinitum (www.virology.ws/ 2014/10/16/the-quarantine-period-for-ebola-virus).
People in the areas of outbreak and in general need to be familiarized with the disease and mechanisms of its transmission. Suspected patients should refrain from breast-feeding and unprotected sex and offer themselves for isolation and diagnosis. Homes of patients after they are quarantined or admitted in hospital should be disinfected.
Barrier Nursing of EVD Patients
Doctors, nurses and other health care givers, including family members/ friends of patients to be engaged for providing medical care to EVD patients must get extensively familiarized about EVD, such that chances of their getting infected are minimised. Towards this end, they must also be provided with pre-prepared protocols and some training. The health care staff, before entering the quarantine or patient care area and while providing medical attention to EVD patients, must wear personal protective equipment (PPE), that leaves no part of skin unprotected. The PPE to be worn includes single use water/fluid-resistant hooded gown/coverall, boot covers that extend upto mid-calf and apron, two sets of nitrile gloves with extended cuffs, full face shield, helmet covered with disposable hood fitted with N95 respirator. When performing any aerosol-generating procedure, a powered air purifier repirator (PAPR) suit may be worn in place of N95 respirator. Training in donning, doffing and use of PPE without accidents is essential (Reiter et al., 1999; Funk and Kumar 2015 and www.phac-aspc.gc .ca/lab-bio/ res/psds-ffss/ebola-eng.php).
Disposal of Materials Used Upon or by EVD Patients and Their Sewage and Cremation of Diseased Corpses
Best procedure torespectively dispose of or decontaminate the medical waste and clothing, eating utensils, linen and other belonging of EVD patients is by incineration or autoclaving in suitably designed devices of large size. Sewage of the quarantined EVD patients or of those hospitalized in special wards should be collected and stored for atleast two weeks at 25 o C and one week at 30 o C for decay of Ebolavirus to occur to an extent of > 99.99% (Bibby et al., 2015; Casanova and Weaver 2015; Judson et al., 2015) . The bodies of the dead EVD patients should be handled by PPE wearing persons. Cremation in closed container would be the best means of containing spread of infection that can result from the conventional funeral.
Steps to Avoid Impending Ebolavirus Disease Epidemic in India
On account of their stability, rapid transmissibilty and fatal disease causing properties, Ebolaviruses have been described as class A bioterror agents. Ebolaviruses are reservoired among the forest animals in Africa. Since it is impossible to eliminate the Ebola reservoir in wild forest animals, EVD outbreaks are expected to occur periodically in different countries of Africa. Eating semi-cooked Ebolavirus containing bush meat which is traded (Maughan 2014) is the main and continuing factor for Ebolavirus outbreaks in Africa (European Centre for Disease Prevention and Control 2014; Casanova and Weaver 2015) . Importation of EVD into countries outside of areas of outbreak will remain a lurking danger. Entry and spread of Ebolavirus in densely populated cities of India will be disastrous. Residents of super-denselypopulated shanty/slum colonies in the cities will be especially vulnerable to Ebolavirus infection. Within India, virus infection could spread from its epicentre to other cities by movement of infected persons. The general absence of immunity against Ebolavirus and population dynamics in densely populated areas in India dictate that the country should prepare for any sudden challenge of EVD importation (Kumar and Gopal 2014) .
A variety of steps, listed below, should be taken urgently and the process improved on a continous basis. Guidelines prepared by the World Health Organization, Centre for Disease Control (CDC, USA) and National Institute of Allergy and Infectious Diseases (NIAID, USA) (http://touch.govexec.com/govexec/#1/entry/ ebola-discussion-moves-how-to-prevent -the-nextepideme, 550ae.; WHO/EVD/Guidance/Sur Non E Count/14.1) are required to be strictly implemented for the safety of travellers and surveillance of travellers by immigration officials and ship and airline services (Jacobson et al., 2016) . General public needs to be made aware of the EVD and hygienic control of infection. The topic of infectious diseases, including EVD should be now included in the curricula of school education. Medical and nursing colleges must have practical and theory courses emphasizing on the emerging infectious diseases, including Ebola. Teams of doctors, nurses and epidemiologists must be composed in all the states and union territories and suitably trained about management of EVD (Funk and Kumar 2015) . Diagnostic laboratories should be established in all the major cities. Mobile diagnostic laboratories should also be constructed with desired safety levels for conducting tests, at foci of disease spread. Hospitals should be identified which will function as the EVD treatment centres under whose charge quarantine facilities will become operational on short notice. Procedures for fool proof case management, contact tracing, quarantining, treatment and safe disposal of contaminated materials and cadavers will be standardized, published and kept ready. The materials to be used in treatment, safeguarding of care givers and prophylaxis will be stockpiled and steps taken to inventorise their speedy procurement and/or manufacture. Some Indian laboratories should initiate research on development of pre-and post-infection drugs effective in preventing and treating EVD, using suitable containment facilities (P4). This work should be broad based against communicable diseases, since there is evidence that some of the therapies may be common to several different virus caused diseases (Table 5) .
Quarantining of infected people is considered the most effective mode for stopping the spread of Ebola virus disease outbreak. To arrest the spread of disease, areas housing the infected persons will need to be isolated from the rest. The needs of quarantined people will be met as above. The procedure to combat EVD epidemic will have to be updated as the vaccines and therapies already at the advanced stages of clinical trial get approved and begin to get manufactured.
Summary and Concluding Remarks
The four known species of filoviridae viral genus Ebola occur in the form of enveloped tubular virion in which 19 kb negative sense single strand RNA genome is encapsulated. Ebola virus genome has seven cistrons that express nine functional proteins/peptides. Ebola viruses are zoonotic. Ebola species, such as Zaire Ebola virus (ZEBOV), which cause highly lethal disease (called Ebola virus disease, EVD) are presently reservoired in wild animals of There have been more than 20 recorded outbreaks of EVD in Africa in last four decades. Till the Ebola reservoir exists, EVD outbreaks will continue to occur sporadically. An outbreak initiates when a human gets exposed to blood or body fluids of infected animal(s) (bat, primate etc.). It then spreads person-to-person nosacomially.
Ebola virions attach to and enter into the cytoplasm of mononuclear phagocytic cells present at the site of infection in mucosal tissue or injured skin, opportunistically. The virus expresses its genes, replicates and assembles pro-virions in host cell cytoplasm which mature at and get released as infective particles from host cell's outer plasma membrane. As the virus multiplies in the dendritic and macrophage cells, the interferons based innate antiviral immune response pathway is overcome by Ebola protein functions. Failure of dyeing infected dendritic cells to activate the adaptive immune response system and consequent T-cell apoptosis and disabling of β-cells and neutrophils allows the virus to multiply rapidly. Immunity suppression allows virus to spread into various organs of the host through blood stream and lymphatic channels. Host launches a pro-inflammatory response by release of chemokines and cytokines. This results in gastro-intestinal dysfunction, coagulation defects, vascular leakages, necrotic failure of organs, drop in blood pressure and shock, altogether leading to death of EVD patient. Presently, there is no approved vaccine or specific medicine for EVD. 
